The meeting presented Dr. Xiangxiang Shi's postdoctoral work at the intersection of biomaterials, drug delivery, and cancer immunotherapy, organized around three research stories: a pro-drug–tethered lipid nanoparticle (LNP) platform for co-delivering small-molecule inhibitors and mRNA, a lung-targeted intravenous mRNA vaccine strategy, and chemical barcoding for multiplexed nanoparticle screening. Dr. Shi... ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­
đź‘‹ You've been invited to view this report because Robin D Terwilliger added Read to the meeting and wanted to share the recap with you.
Qiangqiang Shi - Seminar Purdue AI‑Driven Biomolecular Design, Biotech & Computational Biology Position
March 11, 2026
 
The meeting presented Dr. Xiangxiang Shi's postdoctoral work at the intersection of biomaterials, drug delivery, and cancer immunotherapy, organized around three research stories: a pro-drug–tethered lipid nanoparticle (LNP) platform for co-delivering small-molecule inhibitors and mRNA, a lung-targeted intravenous mRNA vaccine strategy, and chemical barcoding for multiplexed nanoparticle screening. Dr. Shi... see more
Access this meeting report
Account creation required. This is your personal link, please do not forward this email to others.
Recap
Chapters & Topics
•Meeting opening and logistics
•Dr. Xiangxiang Shi presented research on precision nanomaterials for co-delivery of small-molecule drugs and mRNA for cancer immunotherapy.
Action Items
•Crystal D O'Neal will analyze the collected serum and lung tissue samples for cytokine changes and T cell functional markers and report the results.
 
Key Questions
•How can the IDO–kynurenine–AHR pathway that drives T-cell exhaustion be prevented?
•If an IDO inhibitor and IL-12 mRNA are co-encapsulated in one RNP, will therapeutic effects be amplified?
Work smarter, not harder

Work smarter, not harder

Read makes meetings more effective and efficient with meeting recaps, transcripts, playback, personalized coaching, meeting recommendations, and more.

Get started for free →
Need help? Visit the Support Center or contact us.

Team at Read AI • 999 3rd Ave, Suite 3300, Seattle, WA 98104